Tenderwize
Back to tender search

Open-house rebate agreement for Alfacalcidol

AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse·Eisenberg, Germany·Deadline Nov 30, 2027 · 471 days left·Open·Supplies
Original notice title

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Alfacalcidol, ATC A11CC03

52/100

Opportunity Score

Needs reviewMedium complexity
SuppliesOpen
Why this score?

Opportunity

52 / 100

Complexity

58 / 100

Risk factors

The notice requires either handwritten original documents or documents signed with a qualified electronic signature; or...

Only pharmaceutical companies are eligible, and medicines must be authorised and marketable in Germany.

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Overview

Moderate opportunity

Key Facts

  • Supplies contract
  • 1 lot
  • Duration until Jan 2028
  • Non-exclusive open-house rebate agreements for pharmaceutical products containing Alfacalcidol (ATC A11CC03).
  • Supply of only authorised and marketable medicines in Germany.
Show full summary

This is an open-house supply arrangement for pharmaceutical products with AOK Rheinland-Pfalz/Saarland for the active substance Alfacalcidol (ATC A11CC03). It is non-exclusive, open to pharmaceutical companies only, with uniform terms and no individual negotiation. The contract period runs from 01.02.2026 to 31.01.2028, with monthly entry possible during the term. No contract value is stated. Submission is not electronic-only: handwritten originals or electronically signed documents by email are allowed, but the notice says electronic submission is otherwise not allowed. Procurement documents appear available via DTVP, but no procurement document text beyond the TED XML notice was provided for analysis.

Risks

The notice requires either handwritten original documents or documents signed with a qualified electronic signature; or...

Only pharmaceutical companies are eligible, and medicines must be authorised and marketable in Germany.

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Medicines must be authorised and marketable in Germany.

Eligibility

  • Only pharmaceutical companies are eligible as potential contract partners.

Administrative

  • If a product is not listed in Lauer-Taxe at submission time, an AMIce database extract must be provided.

Buyer

Lots (1)

LOT-0001

Open-house rebate agreement for Alfacalcidol

Single lot covering non-exclusive open-house rebate agreements for medicinal products containing Alfacalcidol (ATC A11CC03). The scope excludes medicines on the BfArM list under Section 35(5a) SGB V (children's medicines). Contract terms are uniform for all participants; no individual negotiations. Contract start is earliest 01.02.2026 and contracts may be entered monthly during the 24-month period. The lot information comes from structured data and the XML notice.

SuppliesEU fundedElectronic submission

Location

Eisenberg, Germany

Duration

Jan 2026 - Jan 2028

Category

Pharmaceutical products

Deadline

Deadline Nov 30, 2027

Procurement Details

Publication date
09 Dec 2025
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
817817-2025

Documents (1)

Similar tenders